KR20060009155A - 고순도의 레보플록사신 제조방법 - Google Patents
고순도의 레보플록사신 제조방법 Download PDFInfo
- Publication number
- KR20060009155A KR20060009155A KR1020040056637A KR20040056637A KR20060009155A KR 20060009155 A KR20060009155 A KR 20060009155A KR 1020040056637 A KR1020040056637 A KR 1020040056637A KR 20040056637 A KR20040056637 A KR 20040056637A KR 20060009155 A KR20060009155 A KR 20060009155A
- Authority
- KR
- South Korea
- Prior art keywords
- levofloxacin
- water
- solvent
- butanol
- ethyl acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
실시예 | 용매 종류 및 조성 | 레보플록사신 | |||||
순도 | Imp. B (Decarboxylated) | Imp. C (Des-F) | Imp. D (anti) | Imp. E (Des-Me) | Imp. F (N-Oxide) | ||
1 | 조 레보플록사신 | 99.57 | 0.01 | 0.01 | - | 0.01 | 0.01 |
2 | 메틸아세테이트:물(97:3) | 99.81 | - | - | - | - | - |
3 | 메틸이소부틸케톤:물(98.5:1.5) | 99.83 | - | - | - | - | - |
4 | 에틸아세테이트:물(97:3) | 99.84 | - | - | - | - | - |
5 | t-부탄올:물(95:5) | 99.85 | - | - | - | - | - |
6 | 에틸아세테이트:메틸아세테이트:물 (19.4:77.6:3) | 99.86 | - | - | - | - | - |
7 | 에틸아세테이트:메틸아세테이트:물 (48.5:48.5:3) | 99.88 | - | - | - | - | - |
8 | 에틸아세테이트:메틸아세테이트:물 (77.6:19.4:3) | 99.88 | - | - | - | - | - |
9 | t-부탄올:에틸아세테이트:물 (64.7:32.3:3) | 99.88 | - | - | - | - | - |
10 | t-부탄올:에틸아세테이트:물 (48.5:48.5:3) | 99.90 | - | - | - | - | - |
11 | t-부탄올:에틸아세테이트:물 (32.3:64.7:3) | 99.90 | - | - | - | - | - |
12 | t-부탄올:메틸아세테이트:물 (64.7:32.3:3) | 99.90 | - | - | - | - | - |
13 | t-부탄올:메틸아세테이트:물 (48.5:48.5:3) | 99.89 | - | - | - | - | - |
14 | t-부탄올:메틸아세테이트:물 (32.3:64.7:3) | 99.90 | - | - | - | - | - |
Claims (9)
- 조 레보플록사신(crude levofloxacin)을 극성 용매에 용해한 후 재결정화하여 고순도의 레보플록사신(pure levofloxacin)을 제조하는 방법에 있어서, 조 레보플록사신을 t-부탄올, 메틸아세테이트, 에틸아세테이트, 이소프로필아세테이트 또는 메틸이소부틸케톤의 단일용매, 이들의 혼합용매 및 이들의 수용액으로 구성된 그룹으로부터 선택된 용매에 용해한 후 재결정화하는 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 용매의 물 함량이 용매 전체 부피의 1.5 ~ 6.0 %(v/v)인 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 용매가 t-부탄올 및 에틸아세테이트 혼합용매의 수용액인 것을 특징으로 하는 제조방법.
- 제3항에 있어서, t-부탄올 : 에틸아세테이트 : 물의 혼합비율이 32.3: 64.7: 3 인 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 반응온도가 50℃ ~ 115℃ 에서 수행되는 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 반응온도가 환류온도 범위에서 수행되는 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 얻어진 레보플록사신의 순도가 99.8% 이상인 것을 특징으로 하는 제조방법.
- 제1항에 있어서, 얻어진 레보플록사신은 N-옥사이드-레보플록사신과 데스메틸-레보플록사신을 포함하지 않는 것을 특징으로 하는 제조방법.
- 제1항 내지 제8항 중 어느 한 항에 있어서, 얻어진 레보플록사신이 레보플록사신 반수화물 형태인 것을 특징으로 하는 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040056637A KR100704641B1 (ko) | 2004-07-21 | 2004-07-21 | 고순도의 레보플록사신 제조방법 |
CA2573129A CA2573129C (en) | 2004-07-21 | 2005-07-18 | Process for preparing levofloxacin or its hydrate |
PCT/KR2005/002294 WO2006009374A1 (en) | 2004-07-21 | 2005-07-18 | Process for preparing levofloxacin or its hydrate |
JP2007522417A JP5065020B2 (ja) | 2004-07-21 | 2005-07-18 | レボフロキサシンまたはその水和物の製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040056637A KR100704641B1 (ko) | 2004-07-21 | 2004-07-21 | 고순도의 레보플록사신 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060009155A true KR20060009155A (ko) | 2006-01-31 |
KR100704641B1 KR100704641B1 (ko) | 2007-04-06 |
Family
ID=35785447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040056637A KR100704641B1 (ko) | 2004-07-21 | 2004-07-21 | 고순도의 레보플록사신 제조방법 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5065020B2 (ko) |
KR (1) | KR100704641B1 (ko) |
CA (1) | CA2573129C (ko) |
WO (1) | WO2006009374A1 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629458B2 (en) | 2001-10-03 | 2009-12-08 | Teva Pharmaceutical Industries Ltd. | Preparation of levofloxacin and hemihydrate thereof |
US7964723B2 (en) | 2008-08-02 | 2011-06-21 | Apeloa-Kangyu | And practical process for exclusively producing (S)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido-[1,2,3,de][1,4]benzoxazine-6-carboxylic acid hemihydrate |
CN111855840A (zh) * | 2020-06-30 | 2020-10-30 | 辰欣药业股份有限公司 | 一种盐酸左氧氟沙星注射液中有关物质的检测方法 |
CN116953096A (zh) * | 2022-12-24 | 2023-10-27 | 华夏生生药业(北京)有限公司 | 一种左氧氟沙星注射液杂质检测方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777253A (en) * | 1986-04-25 | 1988-10-11 | Abbott Laboratories | Process for preparation of racemate and optically active ofloxacin and related derivatives |
JP3105572B2 (ja) * | 1990-03-01 | 2000-11-06 | 第一製薬株式会社 | 水和物の選択的製法 |
TW208013B (ko) * | 1990-03-01 | 1993-06-21 | Daiichi Co Ltd | |
KR100309871B1 (ko) * | 1999-02-24 | 2001-10-29 | 윤종용 | (-)피리도벤즈옥사진 카르복실산 유도체의 제조방법 |
AU2002365416A1 (en) * | 2001-11-29 | 2003-06-10 | Teva Pharmaceutical Industries Ltd. | Methods for the purification of levofloxacin |
JP2004099494A (ja) * | 2002-09-09 | 2004-04-02 | Shiono Chemical Co Ltd | 光学活性三環式化合物の製造方法 |
AU2003285625A1 (en) * | 2002-12-16 | 2004-07-09 | Ranbaxy Laboratories Limited | Pure levofloxacin hemihydrate and processes for preparation thereof |
-
2004
- 2004-07-21 KR KR1020040056637A patent/KR100704641B1/ko active IP Right Grant
-
2005
- 2005-07-18 WO PCT/KR2005/002294 patent/WO2006009374A1/en active Application Filing
- 2005-07-18 CA CA2573129A patent/CA2573129C/en not_active Expired - Fee Related
- 2005-07-18 JP JP2007522417A patent/JP5065020B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2008507507A (ja) | 2008-03-13 |
CA2573129A1 (en) | 2006-01-26 |
WO2006009374A1 (en) | 2006-01-26 |
CA2573129C (en) | 2012-10-16 |
KR100704641B1 (ko) | 2007-04-06 |
JP5065020B2 (ja) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3421470A1 (de) | Substituierte 5-fluor-1h-pyrazolopyridine in kristalliner form | |
CN111278830B (zh) | 一种parp抑制剂及其中间体的制备方法 | |
RU2387656C2 (ru) | Способ получения гидробромида галантамина | |
DE60210598T2 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
KR101246392B1 (ko) | 술폰아미드 화합물 및 그 결정 | |
WO2003028665A2 (en) | Methods for the purification of levofloxacin | |
WO2012134392A1 (en) | Process for the production of a pemetrexed salt | |
KR100704641B1 (ko) | 고순도의 레보플록사신 제조방법 | |
CN101863904A (zh) | 一种高纯度左氧氟沙星半水合物的制备方法 | |
CA2466860A1 (en) | Methods for the purification of levofloxacin | |
CN109384767B (zh) | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 | |
EP0647644B1 (de) | Aktibakteriell wirksame Pyrido 1,2,3-d,e 1,3,4 Benzoxadiazinderivate | |
EP2139899B1 (en) | Crystalline forms of topotecan hydrochloride and processes for making the same | |
KR101673979B1 (ko) | 화합물 jk12a 및 그 제조 | |
KR101485418B1 (ko) | 고순도 미르타자핀의 제조방법 | |
AU2021297767A1 (en) | Preparation method for aromatic ether compound | |
CA2278845C (en) | Process for preparing quinolone and naphthyridone carboxylic acids | |
KR20220018486A (ko) | 4-페닐-5-알콕시카르보닐-2-티아졸-2-일-1,4-디히드로피리미딘-6-일]메틸]-3-옥소-5,6,8,8a-테트라히드로-1H-이미다조[1,5-a]피라진-2-일]-카르복실산을 제조하는 대체 방법 | |
US7057041B2 (en) | Process for the preparation of zaleplon | |
EA029363B1 (ru) | Фармацевтические составы, содержащие 3-(4-циннамил-1-пиперазинил)аминопроизводные 3-формил рифамицина sv и 3-формил рифамицина s, и способ их получения | |
WO2021043200A1 (zh) | 一种喹唑啉衍生物的制备方法及其结晶 | |
EP0167045A1 (de) | Benzo (c)(1,8)naphthyridine, Verfahren zu ihrer Herstellung und ihre Verwendung sowie diese Verbindungen enthaltende Zubereitungen | |
CA2858778A1 (en) | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives | |
CN107365299B (zh) | 一种达比加群酯的制备方法及其中间体 | |
CN115141204B (zh) | 一种萘[1,2-b]呋喃-4,5-二酮衍生物其制备及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130109 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140110 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150127 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160108 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180109 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190129 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200213 Year of fee payment: 14 |